Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2022 | Defining high-risk disease in CLL

Lydia Scarfò • 6 Oct 2022
ERIC 2022
Chronic Lymphocytic Leukemia Leukemia

Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, discusses the definition of high-risk disease in chronic lymphocytic leukemia (CLL), commenting on the role of TP53 aberrations and immunoglobulin gene (IgG) mutations as biomarkers with prognostic or predictive value, and highlighting the necessity to find more effective treatments for patients who are resistant to BTK and BCL2 inhibitors. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Lydia Scarfò

1:56
Defining success in CLL
Lydia Scarfò • 8 Oct 2023
2:00
Prevention of TLS with venetoclax-based regimens
Lydia Scarfò • 8 Oct 2023
1:28
Challenges with defining fitness in CLL & important comorbidities to consider when selecting therapy
Lydia Scarfò • 8 Oct 2023
2:08
Choosing between continuous versus fixed-duration therapy in CLL
Lydia Scarfò • 8 Oct 2023

Related Videos

2:00
BTK degraders in CLL and lymphoma: a Phase I trial of NX-5948
Dima El-Sharkawi • 28 Apr 2024
2:04
Increasing awareness of germline predispositions to hematological malignancies in pediatric patients
Anupama Rao • 29 Apr 2024
0:57
The development of a UK AML registry
Priyanka Mehta • 22 Apr 2024
5:27
Young matched unrelated donors versus older-aged matched sibling donors in alloSCT with PTCy
Karthik Nath • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals